- Home
- MRM vs AEON Comparison
MRM vs AEON Comparison
Compare MRM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- AEON
- Stock Information
- Founded
- MRM 2000
- AEON N/A
- Country
- MRM Japan
- AEON United States
- Employees
- MRM N/A
- AEON N/A
- Industry
- MRM Other Consumer Services
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- AEON Health Care
- Exchange
- MRM Nasdaq
- AEON Nasdaq
- Market Cap
- MRM 16.0M
- AEON 13.5M
- IPO Year
- MRM 2020
- AEON N/A
- Fundamental
- Price
- MRM $2.15
- AEON $0.88
- Analyst Decision
- MRM
- AEON Strong Buy
- Analyst Count
- MRM 0
- AEON 1
- Target Price
- MRM N/A
- AEON $7.20
- AVG Volume (30 Days)
- MRM 2.1M
- AEON 407.6K
- Earning Date
- MRM 05-22-2026
- AEON 11-12-2025
- Dividend Yield
- MRM N/A
- AEON N/A
- EPS Growth
- MRM N/A
- AEON N/A
- EPS
- MRM 0.04
- AEON N/A
- Revenue
- MRM $55,915,220.00
- AEON N/A
- Revenue This Year
- MRM N/A
- AEON N/A
- Revenue Next Year
- MRM N/A
- AEON N/A
- P/E Ratio
- MRM $61.67
- AEON N/A
- Revenue Growth
- MRM 12.79
- AEON N/A
- 52 Week Low
- MRM $0.34
- AEON $0.38
- 52 Week High
- MRM $4.45
- AEON $73.44
- Technical
- Relative Strength Index (RSI)
- MRM 48.12
- AEON 45.76
- Support Level
- MRM $2.07
- AEON $0.88
- Resistance Level
- MRM $2.73
- AEON $0.96
- Average True Range (ATR)
- MRM 0.21
- AEON 0.16
- MACD
- MRM -0.04
- AEON -0.03
- Stochastic Oscillator
- MRM 22.07
- AEON 3.61
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.